Specific Biologics has closed an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners to advance gene-editing therapy for ALS.
Amount Raised
$35 Million
Round Type
Series A
TorontoInformation TechnologyBiotechnologyHealth CareScience And EngineeringLending And InvestmentsInvestors
Description
Specific Biologics, a biotechnology company, has secured US$35 million in Series A financing. The funding will be used to develop their lead therapeutic candidate through initial clinical trials for ALS. The round saw participation from various foundational and new investors. This financing aims to create new treatment options for patients suffering from genetic diseases.
Quick answer
Specific Biologics raised $35 Million in a Series A round, dated November 2, 2026. Investors: Seido Capital, DeepWork Capital, Business Development Bank Of Canada, Genesys Capital, Lumira Ventures, adMare BioInnovations and Hatteras Venture Partners. Specific Biologics is based in Toronto, Ontario, Canada.
- How much did Specific Biologics raise?
- Specific Biologics raised $35 Million in a Series A round on November 2, 2026.
- Who invested in Specific Biologics?
- Seido Capital, DeepWork Capital, Business Development Bank Of Canada, Genesys Capital, Lumira Ventures, adMare BioInnovations and Hatteras Venture Partners are named as investors in this round.
- What does Specific Biologics do?
- Specific Biologics Inc. ("Specific") is a venture-backed early-stage biotechnology company on a mission to develop novel gene editing technologies to treat diseases through efficient and precise gene editing.
- Where is Specific Biologics based and how big is it?
- Specific Biologics is based in Toronto, Ontario, Canada. Fundz records about 2 employees.
- Who are the decision-makers at Specific Biologics?
- Fundz holds 4 contacts at Specific Biologics, including the Associate Director - Pipeline Development. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Lending And Investments around the same time
Companies in the same sectors as Specific Biologics that raised within 45 days of this round, from Fundz verified event records.
- Delix Therapeutics raised $100M (Series C) on November 9, 2026.
- MedinCell raised $15M (Debt Financing) on October 13, 2026.
- Lifeplex Science raised $5.3M (Series A) on November 13, 2026.
- BioWraptor raised $1.5M (Pre-Seed) on November 12, 2026.
- Skribe Medical raised $1.6M (Pre-Seed) on November 12, 2026.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
Who to call at Specific Biologics, and when
A new round usually means Specific Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Specific Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Specific Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Specific Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Specific Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSpecific Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.